Specifically, in the SUSTAIN‐6 trial, patients with type 2 diabetes and cardiovascular disease risk had a reduced rate of cardiovascular death, non‐fatal myocardial infarction and non‐fatal stroke when treated with the recently approved GLP‐1 mimetic semaglutide (Marso, Bain, et al., 2016). The gene discussed is GCG; the disease is type 2 diabetes mellitus.